International Research Ltd. is operates in The Strand, Cape Town
and Tel Aviv, Locum International LLC in Florida USA and Locum
International Group Switzerland. The Group is among the top pharmaceutical
generic and pharmaceutical drug development company in the world.
The company researches and develops generic formulations, manufacturing
processes, scale-up and validation commercial sized procedures
and markets generic and innovative controlled release and sterile
pharmaceuticals as well as active pharmaceutical ingredients know-how
and technology, such as the neurobiological innovative drugs (F-CRAB's,
CMZ CR) worldwide in over a 175+ countries. LIG provides and presents
leading FDA and EU approved SOPs, PAIs, analytical methods, ANDAs,
dossiers, seminars, workshops and conferences worldwide, covering
both pharmaceutical and neurobiology (F-CRAB's).
Development - F-CRAB's / CMZ CR
LI computational neuroscientists and neurobiologists in the neurobiology
development and experimental unit are currently developing advanced
default protein folding mechanisms and routes for the F-CRAB RRMS
drugs (relapsing remitting multiple sclerosis family of drugs),
which include the development of the second generation Glatiramer
Acetate Copoxane2 (COP2),
with special reference to the molecular weight spectrum (Av.25+nK
daltons spread and limits/10+nK->25+nK) of the truncated four
amino-acid glatiramer acetate complex, which has a significant
batch-2-batch (B2B-SV+RSD) synthesis variation, requiring advanced
cGMP and QA/QC controls, that differ significantly from the normal
drug synthesis pathways, especially in intermediate QA testing
of the protected intermediates. Impeccable cleaning validation,
stringent controls of starting, intermediate raw materials and
solvents, resulting in significantly tighter batch to batch variations
and B2B RSD's and impurity profiles, using special HPLC column
and gel-filtration analytical methodology techniques.
- Distribution venues
Workshops, lectures and seminars on the F-CRAB RRMS drugs, their
development, synthesis, formulation, proposed default 'protein'
folding, HPLC / gel filtration analysis/A.M validation and associated
e-CTD/CTD specification / parameters are available as per advertised
timetable in both EU and the US journal series (Contact LIG).
The International Journal of Drug Development (IJDD Vol. 10/11)
and the International Journal of Drug R&D (IJDR&D Vol.
11/12) are the main current print venues in the International
Journal Series for publishing the ongoing F-CRAB RRMS drug innovation,
experimental research and product development. Other venues include
International Journal of Drug cGMP (IJGMP) and International Journal
of Drug Validation (IJDV) and International Journal of Drug Master
Formula and Processes (IJDM&P).
85% of Locum's technology sales are in Asia/China/Japan (39),
North America (31) and Europe (30).
For additional information contact LIGroup (www.LocumUSA.com)
or IAGIM (www.iagim.org)